Humanitarian device

Epicel (cultured epidermal autografts) is authorized for use in adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. The effectiveness of the device for this use has not been demonstrated.

Important Safety Information

Epicel is contraindicated in patients with a history of anaphylaxis following exposure to vancomycin, amikacin, and amphotericin, as trace quantities of these anti-infective agents may remain in the Epicel autograft. Epicel should not be used in patients with known sensitivities to materials of bovine or murine origin. It is contraindicated for use on clinically infected wounds.

Epicel product

Regenerate your patient's skin with their own skin cells using Epicel

In the Epicel Clinical Experience databases, 453 patients showed a median take rate at discharge of 75%1

Play

THE EPICEL EXPERIENCE:
A 26-YEAR CASE STUDY*

*Paid testimonial by an Epicel patient. Individual results may vary.

Epicel is indicated for adult and pediatric patients who have deep dermal or full thickness burns comprising a total body surface area greater than or equal to 30%

Consider Epicel for the following patient types

  • Large Burns
    ≥30% TBSA

  • Limited suitable harvest sites
  • Autograft for key functional areas

Specialists are available to answer reimbursement questions about Epicel and the CEA procedure.

Epicel is widely reimbursed and included on a majority of national insurance plans.
Click here to learn more about Epicel reimbursement